Global Substance Abuse (Alcohol, Cocaine, Marijuana, Nicotine) Treatment Market Report 2024-2030: Emerging Trends and Regional Insights for Products and Treatment Options
January 29, 2024 09:07 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
Global Substance Abuse Treatment Market Review and Forecast to 2030: Alcohol Addiction Commanded the Largest Market Share of 34.27% in 2022, Followed by Nicotine Addiction
June 09, 2023 07:23 ET
|
Research and Markets
Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
U.S. Substance Abuse Treatment Market Report 2023: Surging Rate of Drug Addiction and the Growing Prevalence of Alcohol and Smoking Among Teenagers Drives Growth
April 17, 2023 07:43 ET
|
Research and Markets
Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Substance Abuse Treatment Market Research Report by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment,...
InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID
November 07, 2022 06:00 ET
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug...
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
November 03, 2022 08:45 ET
|
Love Pharma Inc.
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a...
InvestmentPitch Media Video Discusses LOVE Pharma’s Pending Acquisition of Naltrexone Therapeutics Supported by Reports that Naltrexone Demonstrates Promising Long COVID Applications
October 21, 2022 06:00 ET
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) which on October 11th signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics,...
North America Addictions Therapeutics Market Report 2020-2027: Focus on Nicotine, Alcohol & Opioid Addiction Treatment
January 22, 2021 08:08 ET
|
Research and Markets
Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "North America Addictions Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Treatment Type; Drug Type; Treatment Center;...
BioCorRx’s Director Louis Lucido Appeared Today on Yahoo Finance LIVE “On the Move”
July 22, 2019 14:03 ET
|
BioCorRx Inc
ANAHEIM, CA, July 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction...
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
March 28, 2019 08:00 ET
|
BioCorRx Inc
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse...
BioCorRx Announces Formation of Scientific Advisory Board
February 19, 2019 10:26 ET
|
BioCorRx Inc
ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...